JANX Janux Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JANX

Price (delayed)

$16.52

Market cap

$1.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$1B

?
Relative Growth: Rel. Growth: 50
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 39

Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms ...

Highlights
JANX's gross profit has soared by 75% QoQ
The revenue has soared by 75% from the previous quarter
The quick ratio has dropped by 65% year-on-year and by 4% since the previous quarter
JANX's equity is down by 6% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.januxrx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of JANX

JANX stock price

How has the Janux Therapeutics stock price performed over time
Intraday
-5.44%
1 week
1.69%
1 month
-5%
1 year
-28.11%
YTD
19.71%
QTD
7.55%

Financial performance

How have Janux Therapeutics's revenue and profit performed over time
Revenue
$24M
Gross profit
$24M
Operating income
-$143.56M
Net income
-$102.59M
Gross margin
100%
Net margin
-427.5%
Janux Therapeutics's net margin has surged by 98% YoY and by 49% QoQ
The operating margin has soared by 98% YoY and by 48% from the previous quarter
JANX's gross profit has soared by 75% QoQ
The revenue has soared by 75% from the previous quarter

Price vs fundamentals

How does JANX's price correlate with its fundamentals

Growth

What is Janux Therapeutics's growth rate over time

Valuation

What is Janux Therapeutics stock price valuation
P/E
N/A
P/B
1.09
P/S
43.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.77
The EPS has grown by 11% from the previous quarter and by 8% YoY
JANX's P/B is 39% below its 5-year quarterly average of 1.9 but 4.5% above its last 4 quarters average of 1.1
JANX's equity is down by 6% year-on-year
The P/S is 84% less than the 5-year quarterly average of 289.0 and 46% less than the last 4 quarters average of 85.2
The revenue has soared by 75% from the previous quarter

Efficiency

How efficient is Janux Therapeutics business performance
The ROS has soared by 98% YoY and by 49% from the previous quarter
The return on invested capital is up by 16% year-on-year and by 9% since the previous quarter
The ROA has grown by 10% from the previous quarter and by 8% YoY
JANX's return on equity is up by 8% since the previous quarter and by 6% year-on-year

Dividends

What is JANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JANX.

Financial health

How did Janux Therapeutics financials performed over time
The total liabilities has soared by 91% YoY but it has contracted by 8% from the previous quarter
The current ratio has plunged by 65% YoY and by 3.9% from the previous quarter
Janux Therapeutics's debt is 98% lower than its equity
JANX's equity is down by 6% year-on-year
Janux Therapeutics's debt has decreased by 5% YoY and by 2.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.